Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1694151 | 1.00 | KMT2A (0.41) | KMT2AMEN1PRMT5WDR77CA1 | |
| SCHEMBL1787921 | 1.00 | KMT2A (0.41) | KMT2AMEN1PRMT5WDR77CA1 | |
| SCHEMBL1720326 | 1.00 | KMT2A (0.41) | KMT2AMEN1PRMT5WDR77CA1 | |
| SCHEMBL981027 | 1.00 | KMT2A (0.41) | KMT2AMEN1PRMT5WDR77CA1 | |
| SCHEMBL981024 | 1.00 | KMT2A (0.41) | KMT2AMEN1PRMT5WDR77CA1 | |
| SCHEMBL28290358 | 0.85 | KMT2A (0.43) | KMT2AMEN1ALDH1A1MCOLN3POLB | |
| SCHEMBL28290356 | 0.85 | KMT2A (0.43) | KMT2AMEN1ALDH1A1MCOLN3POLB | |
| SCHEMBL20502306 | 0.82 | PRMT5 (0.44) | KMT2AMEN1PRMT5WDR77ALDH1A1 | |
| SCHEMBL28853079 | 0.82 | KMT2A (0.34) | KMT2AMEN1PRMT5WDR77ALDH1A1 | |
| SCHEMBL28853081 | 0.82 | KMT2A (0.34) | KMT2AMEN1PRMT5WDR77ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118126009-A | Coumarin derivative, preparation method and application | 成都纽瑞特医疗科技股份有限公司 | 2024-06-04 | — | — | CN | claimed |
| EP-2860175-B1 | METHOD FOR PRODUCING 4,4,7-TRIFLUORO-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE COMPOUND AND INTERMEDIATE FOR SYNTHESIS THEREOF | TACURION (US) | 2017-11-29 | — | — | EP | claimed |
| CN-118126009-A | Coumarin derivative, preparation method and application | 成都纽瑞特医疗科技股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-11701373-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220331346-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-20 | — | — | US | disclosed |
| US-11229646-B2 | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2022-01-25 | — | — | US | disclosed |
| US-11058696-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3183242-B1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-108047145-B | 2-arylquinoxaline compound with affinity with Tau protein and preparation method and application thereof | 北京师范大学 | 2020-12-15 | — | — | CN | disclosed |
| US-20200330462-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| US-20200281952-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-10 | — | — | US | disclosed |
| WO-1995002583-A1 | PROCESS FOR MAKING HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1994022846-A1 | COMPOUNDS ENHANCING ANTITUMOR ACTIVITY OF OTHER CYTOTOXIC AGENTS | PFIZER INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| US-5218114-A | For treating diseases of gastrointestinal or central nervous systems | MERCK & CO., INC. (US) | 1993-06-08 | — | — | US | disclosed |
| US-5204463-A | Substituted methoxyphenyl-4,5 dihydro-3(2H)-pridazinones having cardiotonic and beta blocking activities | GLAXO INC. (US) | 1993-04-20 | — | — | US | disclosed |
| EP-0508799-A1 | Cholecystokinin antagonists | MERCK & CO. INC. (US) | 1992-10-14 | — | — | EP | disclosed |
| US-5096904-A | Congestive heart failure | GLAXO INC. (US) | 1992-03-17 | — | — | US | disclosed |
| US-5084463-A | Cardiovascular disorders | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-01-28 | — | — | US | disclosed |
| US-5053338-A | Hydrolysis of ester to obtain an optically enriched mixture of a phenol enantiomer | GLAXO INC. (US) | 1991-10-01 | — | — | US | disclosed |
| EP-0412814-A2 | Pyridazinones having cardiotonic and beta blocking activity | GLAXO WELLCOME INC. (US) | 1991-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200330462-A1 | TRICYCLIC NITROGEN CONTAINING COMPOUNDS FOR TREATING NEISSERIA GONORRHOEA INFECTION | NME2, NNMT, NGLY1 | KMT2A 3610/4885MEN1 1686/4885PRMT5 1509/4885 |
| US-20200281952-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | KMT2A 3470/4885MEN1 2180/4885PRMT5 2799/4885 |
| US-20220331346-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | KMT2A 3470/4885MEN1 2180/4885PRMT5 2799/4885 |
| US-11701373-B2 | Substituted bicyclic compounds | S1PR1, S1PR3, S1PR2 | KMT2A 3470/4885MEN1 2180/4885PRMT5 2799/4885 |
| US-11058696-B2 | Substituted bicyclic compounds | S1PR1, S1PR3, S1PR2 | KMT2A 3470/4885MEN1 2180/4885PRMT5 2799/4885 |
| US-11229646-B2 | Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione | GMPS, GNE, DHPS | KMT2A 1748/4885MEN1 2729/4885PRMT5 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.